Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
01-Apr-2025 | 8,602 | 8,748.5 | 8,463.25 | 8,492.65 | 8,391 | 19,04,13,493.95 | 9,638 |
02-Apr-2025 | 8,452.65 | 8,518 | 8,052.65 | 8,094.5 | 11,833 | 34,10,54,409.7 | 17,982 |
03-Apr-2025 | 8,099.9 | 8,297.85 | 7,681 | 8,068.55 | 21,002 | 61,22,41,328.75 | 16,572 |
04-Apr-2025 | 8,012.4 | 8,199.85 | 7,857.05 | 7,904 | 8,051 | 22,97,05,830.45 | 11,984 |
07-Apr-2025 | 7,351 | 8,080 | 7,201.15 | 7,868.7 | 11,188 | 23,00,44,795.35 | 7,770 |
08-Apr-2025 | 7,928.65 | 8,148.25 | 7,928.65 | 8,062.25 | 13,025 | 25,58,07,399.75 | 16,399 |
09-Apr-2025 | 8,046.8 | 8,238.85 | 7,952.4 | 8,021.05 | 8,826 | 22,00,65,908.75 | 8,979 |
11-Apr-2025 | 8,222 | 8,525.5 | 8,142.75 | 8,457.4 | 12,230 | 33,94,31,671.45 | 17,863 |
15-Apr-2025 | 8,525 | 8,940 | 8,485.5 | 8,873.5 | 24,003 | 70,90,74,772 | 41,623 |
16-Apr-2025 | 8,870 | 9,167.5 | 8,424 | 8,514.5 | 17,568 | 51,09,03,388.5 | 18,731 |
17-Apr-2025 | 8,506 | 8,780 | 8,505 | 8,746 | 10,068 | 27,69,75,797.5 | 12,331 |
21-Apr-2025 | 8,746 | 8,902 | 8,700 | 8,727.5 | 5,711 | 11,82,62,942 | 4,504 |
22-Apr-2025 | 8,791 | 9,088 | 8,655 | 8,971.5 | 6,888 | 21,70,06,892 | 7,343 |
23-Apr-2025 | 8,999 | 9,140 | 8,925 | 9,042 | 5,448 | 19,36,56,785.5 | 7,999 |
24-Apr-2025 | 9,040 | 9,211 | 8,930 | 8,967.5 | 6,863 | 17,18,56,177 | 5,508 |
25-Apr-2025 | 8,922.5 | 8,991.5 | 8,550 | 8,725 | 6,203 | 15,99,75,997.5 | 6,703 |
28-Apr-2025 | 8,725 | 8,916 | 8,650.5 | 8,840 | 6,046 | 10,97,58,933.5 | 3,863 |
29-Apr-2025 | 8,830 | 8,930 | 8,760 | 8,794.5 | 3,228 | 7,03,16,165.5 | 2,765 |
The approval is for two dosing forms: 120 mg/2.4 ml and 500 mg/10 ml.
The company may import the powder form of sodium zirconium cyclosilicate for preparation of oral suspension as Lokelma in 5 g and 10 g formulation.
As per the reported property consultants, the company has issued a global mandate for selecting candidates for the said land deal.
It is used with Durvalumab to treat advanced or recurrent endometrial cancer in patients whose disease has not progressed after first-line treatment.
This combination drug is used to treat chronic obstructive pulmonary disease (COPD) in adults, relieving symptoms and preventing exacerbations.
For the first half (H1) of FY25, the revenue rose to ₹795.5 Crore, driven by growth in oncology, biopharmaceuticals, and rare disease segments.
The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.
The said indication is for the use of durvalumab in combination with chemotherapy as a neoadjuvant treatment.
Here are some of the stocks that may see significant price movement today: Punjab National Bank, NTPC, Power Grid, etc.
The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
